Who is sponsoring NCT01602939?

NCT01602939 is sponsored by Hospital Virgen de la Salud.

What condition does NCT01602939 study?

NCT01602939 studies Systemic Mastocytosis.

What drugs are being tested in NCT01602939?

Interventions: Cladribine and pegylated interpheron alpha-2a.

What is the status of NCT01602939?

NCT01602939 is currently UNKNOWN.

Last reviewed 2016-08-26 · How we verify

Subcutaneous Cladribine Plus Pegylated Interpheron Alfa-2a in Advanced Systemic Mastocytosis With D816V and Other Exon 17 KIT Mutations.

NCT01602939 Phase 2/Phase 3 UNKNOWN

The aim of this study is to evaluate the efficacy in terms of clinical and biological response rates of Cladribine plus Pegylated Interpheron alpha-2a therapy in patients with advanced systemic mastocytosis carrying D816V or other exon 17 KIT mutations.

Details

Lead sponsor	Hospital Virgen de la Salud
Phase	Phase 2/Phase 3
Status	UNKNOWN
Enrolment	10
Start date	2012-05
Completion	2017-06

Conditions

Systemic Mastocytosis

Interventions

Cladribine and pegylated interpheron alpha-2a

Primary outcomes

To evaluate the effect of therapy on bone marrow mast cell infiltration. — 6 months
Evaluation of bone marrow response will be assessed by immunohistochemestry, citology, flow cytometry and molecular analyses of bone marrow samples.

Countries

Spain